Molecular and cellular determinants of L-Dopa-induced dyskinesia in Parkinson’s Disease
Abstract Treatment with L-3,4-dihydroxyphenylalanine (L-Dopa) compensates for decreased striatal dopamine (DA) levels and reduces Parkinson’s disease (PD) symptoms. However, during disease progression, L-Dopa-induced dyskinesia (LID) develops virtually in all PD patients, making the control of PD sy...
Saved in:
| Main Authors: | Federica Servillo, Maria De Carluccio, Giulia Di Lazzaro, Federica Campanelli, Gioia Marino, Giuseppina Natale, Ada Ledonne, Mariangela Massaro Cenere, Emanuela Paldino, Daniela Di Giuda, Anna Picca, Francesco Bove, Riccardo Di Iorio, Benedetta Angeloni, Angelo Tiziano Cimmino, Giovanni Bellomo, Barbara Picconi, Anna Rita Bentivoglio, Nicola Biagio Mercuri, Lucilla Parnetti, Veronica Ghiglieri, Maria Teresa Viscomi, Paolo Calabresi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-11-01
|
| Series: | npj Parkinson's Disease |
| Online Access: | https://doi.org/10.1038/s41531-024-00836-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Corticostriatal Plastic Changes in Experimental L-DOPA-Induced Dyskinesia
by: Veronica Ghiglieri, et al.
Published: (2012-01-01) -
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
by: Katharina Bolsewig, et al.
Published: (2025-01-01) -
Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers
by: Anna L. Wojdała, et al.
Published: (2025-01-01) -
Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
by: Alessia Lanari, et al.
Published: (2009-01-01) -
Studying Alzheimer’s disease through an integrative serum metabolomic and lipoproteomic approach
by: Alessia Vignoli, et al.
Published: (2025-01-01)